Premature arteriosclerosis in HIV-infected patients? Current status;Vorzeitige arteriosklerose bei HIV-infizierten patienten? Aktueller stand

Herz

Volumn 30, Issue 6, 2005, Pages 467-471

  Hoffmann, Christian ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cardiovascular events; HAART; HIV; Myocardial infarction

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DYSLIPIDEMIA; EPIDEMIC; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; METABOLIC DISORDER; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARTERIOSCLEROSIS; CAUSALITY; CLINICAL TRIALS; COMORBIDITY; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; INCIDENCE; MYOCARDIAL INFARCTION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 25444491955     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2721-6     Document Type: Review

References (49)

1. Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet 1997;349:1819.
2. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
3. Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958.
4. Blum A, Hadas V, Burke M, et al. Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 2005;28:149-53.
5. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
6. Christeff N, Lortholary O, Casassus P, et al. Serum lipid concentration with reference to the clinical and immunological status of HIV-infected men. Ann Med Interne (Paris) 1995;146:490-5.
7. Conaldi PG, Serra C, Toniolo A, et al. Productive HIV-infection of human vascular endothelial cell requires cell proliferation and is stimulated by combined treatment with interleukin-1β plus tumor necrosis factor. J Med Virol 1995;47:355-63.
8. Constans J, Pellegrin J, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20.
9. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003;19:449-55.
10. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-33.
11. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002;34:98-102.
12. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy. AIDS 2001;15:329-34.
13. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1475-8.
14. El-Sadr W, Reiss P, De Wit S, et al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. Presented at the 12th CROI, Boston, February 22-25, 2005. abstract 42.
15. Friedl AC, Jost CH, Schalcher C, et al. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 2000;14:2790-2.
16. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
17. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
18. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-9.
19. Garcia-Benayas T, Blanco F, Alcolea A, et al. Short communication: Benefits in the lipid profile after substitution of abacavir for stavudine: a 48-week prospective study. AIDS Res Hum Retroviruses 2004;20:1289-92.
20. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63:1679-93.
21. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
22. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
23. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004;350:730-2.
24. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
25. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-8.
26. Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res Hum Retroviruses 1999;15:1265-77.
27. Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999;13:1796-7.
28. Klein D, Hurley LB, Quesenberry CP Jr, et al. Doprotease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J AIDS 2002;30:471-7.
29. Klein D, Hurley L, Quesenberry C. Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: additional follow-up and changes in practice. Presented at the 12th CROI, Boston, February 22-25, 2005.abstract 869.
30. Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunction in HIV infection. J AIDS 1992;5:127-31.
31. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123-8.
32. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86.
33. Meenan J, Mooney E, Mosquita N, et al. The impact of HIV disease progression on serum lipoproteins. AIDS 1992;6:1551-2.
34. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1-infected patients using carotid intima-media thickness measurement. Ann Med 2002;34:55-63.
35. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J AIDS 2005;39:174-80.
36. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J AIDS 2000;23:35-43.
37. Nolan D, Watts GF, Herrmann SE, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Q J Med 2003;96:825-32.
38. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137-44.
39. Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144:225-31.
40. Quiros-Roldan E, Torti C, et al. Risk factors for myocardial infarction in HIV-positive patients. Int J STD AIDS 2005;16:14-8.
41. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329-33.
42. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433-8.
43. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early HIV-1 infection. Am J Med 1993;94:515-9.
44. Stein J, Klein D, Bellehumeur J, et al. Use of HIV-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.
45. Tabib A, Greenland T, Mercier I, et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet 1992;340:730.
46. Talwani R, Falusi OM, Mendes de Leon CF, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J AIDS 2002;30:191-5.
47. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19.
48. Zangerle R, Sarcletti M, Gallati H, et al. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J AIDS 1994;7:1149-56.
49. Zietz C, Hotz B, Sturzl M, et al. Aortic endothelium in HIV-1 infection:chronic injury, activation, and increased leukocyte adherence. Am J Pathol 1996;149:1887-98.